Byungwoo Ryu, PhD

Assistant Professor, Dermatology

Byungwoo Ryu
(617) 638-5535
609 Albany St (J Bldg)

Biography

Dr. Ryu joined the Department of Dermatology at the Boston University of School of Medicine as an assistant Professor in 2011. He received his Ph.D. degree from Oregon State University in Molecular Toxicology. Dr. Ryu completed his postdoctoral fellowships at the National Cancer Institute in Bethesda, Maryland and Sidney Kimmel Comprehensive Cancer Center at the Johns Hopkins University School of Medicine, Baltimore, Maryland. Dr. Ryu served as an assistant member of the Nevada Cancer Institute at Las Vegas, Nevada and clinical assistant professor of medicine at the University of Nevada School of Medicine at Reno, Nevada. Dr. Ryu is a recipient of Howard Temin Award, career development award (K01), from the National Cancer Institute.

Dr. Ryu’s research interest is to determine the molecular events that dictate melanoma tumorigenicity and malignant progression. It is likely that identification of such molecular pathways will allow us to identify clinically useful biomarkers as well as potential therapeutic targets against this lethal form of skin cancer.

Biomarkers for melanoma progression: Dr. Ryu’s laboratory currently focuses on discovery of molecular biomarkers that can be used for patient stratification and personalized therapy. His laboratory uses genomic and molecular profiling techniques on tissue and blood samples from melanoma patients to find patterns of molecular signatures and correlate them with clinical outcomes.

Therapeutic targeting of metastasis-initiating cells (MICs): Despite recent progress, the molecular mechanisms of tumor metastasis remain unclear. Isolation and dissection of the MICs, subpopulation of tumor cells including circulating cancer cells in patient’s blood, will shed light on the molecular events of metastasis progression. Dr. Ryu’s laboratory focuses on the genetic and epigenetic characterization of the MICs as well as developing therapeutic and preventive strategies of cancer metastasis by targeting the MICs.

Education

  • Oregon State University, PhD
  • Chonbuk National University, MS
  • Chonbuk National University, BS

Publications

  • Published on 4/24/2015

    Hwang S, Kim HE, Min M, Raghunathan R, Panova IP, Munshi R, Ryu B. Epigenetic Silencing of SPINT2 Promotes Cancer Cell Motility via HGF-MET Pathway Activation in Melanoma. J Invest Dermatol. 2015 Sep; 135(9):2283-91. PMID: 25910030.

    Read at: PubMed
  • Published on 6/11/2014

    Rossi M, Tuck J, Kim OJ, Panova I, Symanowski JT, Mahalingam M, Riker AI, Alani RM, Ryu B. Neuropilin-2 gene expression correlates with malignant progression in cutaneous melanoma. Br J Dermatol. 2014 Aug; 171(2):403-8. PMID: 24359286.

    Read at: PubMed
  • Published on 8/22/2013

    Cao J, Wan L, Hacker E, Dai X, Lenna S, Jimenez-Cervantes C, Wang Y, Leslie NR, Xu GX, Widlund HR, Ryu B, Alani RM, Dutton-Regester K, Goding CR, Hayward NK, Wei W, Cui R. MC1R is a potent regulator of PTEN after UV exposure in melanocytes. Mol Cell. 2013 Aug 22; 51(4):409-22. PMID: 23973372.

    Read at: PubMed
  • Published on 5/1/2013

    Ryu B, Hwang S, Alani RM. MicroRNAs as an emerging target for melanoma therapy. J Invest Dermatol. 2013 May; 133(5):1137-9. PMID: 23594536.

    Read at: PubMed
  • Published on 4/18/2013

    Yan G, Eller MS, Elm C, Larocca CA, Ryu B, Panova IP, Dancy BM, Bowers EM, Meyers D, Lareau L, Cole PA, Taverna SD, Alani RM. Selective inhibition of p300 HAT blocks cell cycle progression, induces cellular senescence, and inhibits the DNA damage response in melanoma cells. J Invest Dermatol. 2013 Oct; 133(10):2444-52. PMID: 23698071.

    Read at: PubMed
  • Published on 1/23/2013

    Liu F, Cao J, Wu J, Sullivan K, Shen J, Ryu B, Xu Z, Wei W, Cui R. Stat3-targeted therapies overcome the acquired resistance to vemurafenib in melanomas. J Invest Dermatol. 2013 Aug; 133(8):2041-9. PMID: 23344460.

    Read at: PubMed
  • Published on 3/31/2011

    Ryu B, Moriarty WF, Stine MJ, DeLuca A, Kim DS, Meeker AK, Grills LD, Switzer RA, Eller MS, Alani RM. Global analysis of BRAFV600E target genes in human melanocytes identifies matrix metalloproteinase-1 as a critical mediator of melanoma growth. J Invest Dermatol. 2011 Jul; 131(7):1579-83. PMID: 21451543.

    Read at: PubMed
  • Published on 2/15/2011

    Stine MJ, Wang CJ, Moriarty WF, Ryu B, Cheong R, Westra WH, Levchenko A, Alani RM. Integration of genotypic and phenotypic screening reveals molecular mediators of melanoma-stromal interaction. Cancer Res. 2011 Apr 1; 71(7):2433-44. PMID: 21324919.

    Read at: PubMed
  • Published on 8/18/2010

    Kim HE, Symanowski JT, Samlowski EE, Gonzales J, Ryu B. Quantitative measurement of circulating lymphoid-specific helicase (HELLS) gene transcript: a potential serum biomarker for melanoma metastasis. Pigment Cell Melanoma Res. 2010 Dec; 23(6):845-8. PMID: 20727106.

    Read at: PubMed
  • Published on 9/1/2008

    Cummings SD, Ryu B, Samuels MA, Yu X, Meeker AK, Healey MA, Alani RM. Id1 delays senescence of primary human melanocytes. Mol Carcinog. 2008 Sep; 47(9):653-9. PMID: 18240291.

    Read at: PubMed

View 20 more publications: View full profile at BUMC

View all profiles